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Background: Perform a systematic review and meta-analysis of SARS-CoV-2 infection and pregnancy.
Methods: Databases (Medline, Embase, Clinicaltrials.gov, Cochrane Library) were searched electronically on
6th April and updated regularly until 8th June 2020. Reports of pregnant women with reverse transcription
PCR (RT-PCR) confirmed COVID-19 were included. Meta-analytical proportion summaries and meta-regres-
sion analyses for key clinical outcomes are provided.
Findings: 86 studies were included, 17 studies (2567 pregnancies) in the quantitative synthesis; other small
case series and case reports were used to extract rarely-reported events and outcome. Most women (73.9%)
were in the third trimester; 52.4% have delivered, half by caesarean section (48.3%). The proportion of Black,
Asian or minority ethnic group membership (50.8%); obesity (38.2%), and chronic co-morbidities (32.5%)
were high. The most commonly reported clinical symptoms were fever (63.3%), cough (71.4%) and dyspnoea
(34.4%). The commonest laboratory abnormalities were raised CRP or procalcitonin (54.0%), lymphopenia
(34.2%) and elevated transaminases (16.0%). Preterm birth before 37 weeks’ gestation was common (21.8%),
usually medically-indicated (18.4%). Maternal intensive care unit admission was required in 7.0%, with intu-
bation in 3.4%. Maternal mortality was uncommon (~1%). Maternal intensive care admission was higher in
cohorts with higher rates of co-morbidities (beta=0.007, p<0.05) and maternal age over 35 years
(beta=0.007, p<0.01). Maternal mortality was higher in cohorts with higher rates of antiviral drug use
(beta=0.03, p<0.001), likely due to residual confounding. Neonatal nasopharyngeal swab RT-PCR was posi-
tive in 1.4%.
Interpretation: The risk of iatrogenic preterm birth and caesarean delivery was increased. The available evi-
dence is reassuring, suggesting that maternal morbidity is similar to that of women of reproductive age. Ver-
tical transmission of the virus probably occurs, albeit in a small proportion of cases.
Funding: N/A
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)epartment of Obstetrics and
dation Trust, Blackshaw Road,
.uk (A. Khalil).
Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
RS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and
0), https://doi.org/10.1016/j.eclinm.2020.1004461. Introduction
The outbreak of a novel coronavirus (SARS-CoV-2 which causes
COVID-19) was first reported in Wuhan, China in December 2019,
Research in context
Evidence before this study
Large studies of pregnancy outcomes following SARS-CoV-2 infec-
tion in pregnancy are lacking. These studies are unlikely to be
available in the near future, as each centre has small numbers of
confirmed infections in pregnancy and networks will report only
in the fullness of time. A recent systematic review reported an
aggregate summary of all coronavirus-related illnesses, concluding
that the risks of miscarriage, pre-eclampsia, preterm birth, and
perinatal death are higher; however, similar pregnancy outcomes
across the coronavirus family were assumed. Other systematic
reviews have reported data from less than 500 pregnancies and
lackedmethodological robustness.
Added value of this study
In this systematic review, we searched multiple databases (Med-
line, Embase, Clinicaltrials.gov, Cochrane Library) to 8th June 2020.
We summarized the available evidence on the clinical features,
laboratory and radiological findings, as well as the pregnancy and
neonatal outcomes; 86 studies were included, 17 studies (2567
pregnancies) in the quantitative synthesis; other small case series
and case reports were used to extract rarely-reported events and
outcomes. Most women (73.9%) were in the third trimester; 52.4%
have delivered, half by caesarean section (48.3%). The proportion
of Black, Asian or minority ethnic group membership (50.8%); obe-
sity (38.2%), and chronic co-morbidities (32.5%) were high. The
most commonly reported clinical symptoms were fever (63.3%),
cough (71.4%) and dyspnoea (34.4%). The commonest laboratory
abnormalities were raised CRP or procalcitonin (54.0%), lymphope-
nia (34.2%) and elevated transaminases (16.0%). Preterm birth
before 37 weeks’ gestation was common (21.8%), usually medi-
cally-indicated (18.4%). Maternal intensive care unit admission
was required in 7.0%, with intubation in 3.4%. Maternal mortality
was uncommon (~1%). Maternal intensive care admission was
higher in cohorts with higher rates of co-morbidities and maternal
age over 35 years. Neonatal nasopharyngeal swab RT-PCR was
positive in 1.4%.
Implications of all the available evidence
This meta-analysis includes the largest number of pregnancies
with SARS-CoV-2 reported to date. The study has raised con-
cerns about heightened risks of iatrogenic preterm birth, Cae-
sarean delivery, and possibly, transmission to the newborn
before or after birth, while providing reassuring evidence that
women and babies are not at increased risk of serious illness.
These data are important to inform counselling of women dur-
ing the pandemic, and encourage them to seek both antenatal
care, routine or related to specific problems. While further
information about the direct and indirect implications of the
pandemic will become available from SARS-CoV-2 networks in
the future and may inform care in future pandemics, the data
presented here are needed to inform current care throughout
the current pandemic and future waves.
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few weeks, the virus had spread rapidly throughout China, and
within a month, worldwide. On the 11th of March 2020, this SARS-
CoV-2 outbreak was recognised as a pandemic by the World Health
Organization (WHO) [1]. As of the 1st June 2020, over 6 million cases
have been diagnosed in 210 countries, with a total of 379,728 deaths.
Previous smaller coronavirus outbreaks (i.e., Severe Acute Respiratory
Syndrome [SARS] and Middle East Respiratory Syndrome [MERS] [2-4])Please cite this article as: A. Khalil et al., SARS-CoV-2 infection in pregna
pregnancy outcomes, EClinicalMedicine (2020), https://doi.org/10.1016/jhave associated infection in pregnancy with more serious illness and
preterm birth, although information has been primarily from small
observational studies and case series [2-4]. Concern about the implica-
tions of COVID-19 in pregnancy is further fuelled by its reproductive
capacity, the scale of the outbreak, and the societal response.
A recent systematic review has reported an aggregate summary of
all coronavirus-related illnesses (SARS and MERS included) and con-
cluded that the risk of miscarriage, preeclampsia, preterm birth, and
perinatal death is higher [5]. However, this review included few data
for outcomes related to SARS-CoV-2 and emphasised the rapid rate of
accumulating evidence and the need for updates.
We aimed to systematically review the available literature on COVID-
19 and pregnancy, to provide comprehensive data to care-providers,
pregnant women and their families, inform national and international
guidelines, and direct the course of ongoing and future studies [6,7].
2. Methods
This review was performed according to established methodology
for systematic reviews and meta-analysis. Medline, Embase, Clinical-
trials.gov and Cochrane Library databases were searched electroni-
cally (April 6th 2020) and updated on April 13th 2020 and May 7th
2020, utilising combinations of the relevant medical subject heading
(MeSH) terms, key words, and word variants for “COVID-19” and
“pregnancy” (Supplementary Table 1). After May 7th 2020, the litera-
ture update was performed manually on a weekly basis until June 8st
2020. Grey literature was not searched as double-reporting could not
be ascertained. Reference lists of relevant articles and reviews were
hand-searched for additional reports. PRISMA and MOOSE guidelines
were followed [8,9]. The study was registered with the PROSPERO
database (Registration number: CRD42020178004).
2.1. Study selection and data collection
Maternal outcomes included the clinical COVID-19 presentation
and associated laboratory findings, maternal complications, and
treatment received. Obstetric complications included preterm birth,
stillbirth, mode of delivery and fetal distress. Perinatal outcomes
included perinatal death and evidence of vertical transmission. Any
outcome not explicitly mentioned was considered not to have been
reported. For laboratory parameters, reported local reference ranges
were used to define abnormal.
Case reports, case series, cohort, case-control studies and rando-
mised controlled trials were eligible for inclusion. Studies that
reported on women with PCR confirmed SARS-CoV-2 infection were
eligible for inclusion. Clinically diagnosed cases, conference abstracts,
expert opinions, and critical appraisals were excluded. Two authors
(EK, CB) reviewed all abstracts independently. Agreement regarding
potential relevance was reached by consensus (AK, EK, CB); full text
copies of those papers were obtained and the same two reviewers
independently extracted relevant data regarding study characteris-
tics and maternal and perinatal outcomes. Inconsistencies were dis-
cussed by the reviewers and consensus reached or by discussion with
a third author (AK). If more than one study was published on the
same patients with identical endpoints, the report containing the
most comprehensive (larger patient numbers) information was
included. Individual cases were cross-checked with reports from the
same hospital, whenever possible. If there was suspicion that a case
report or series was subject to double-reporting, and this could not
be confirmed, the publication was excluded; this included aggregate
reports frommultiple centres which previously published case series.
2.2. Quality assessment
Quality assessment of included studies was performed using the
Newcastle-Ottawa Scale (NOS) or modified NOS for case-control,ncy: A systematic review and meta-analysis of clinical features and
.eclinm.2020.100446
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study groups (score 0-4), comparability of the groups (score 0-2), and
ascertainment of outcomes (score 0-3). Two authors (EK, CB) scored
all studies independently. Agreement was reached by consensus and
a third author was involved (AK) in disputed cases.
2.3. Statistical Analysis
For women infected with SARS-CoV-2 in pregnancy, demographic
and disease characteristics were analysed descriptively. A random-
effect meta-analysis of proportions was used to estimate the pooled
rates of each outcome in all pregnancies, and a random-intercept
logistic regression meta-analysis with continuity correction used for
outcomes where there was at least one event in available studies.
Proportion meta-analysis was performed for studies (sample size
>15) that reported on all available cases over a defined time period.
A narrative synthesis was undertaken when few events were
reported from small case series. Between-study heterogeneity was
explored using the I2 statistic, with >50% reflecting substantial het-
erogeneity. In some studies reporting only summary statistics (mean
and standard deviation or median and interquartile range), Monte-
Carlo simulations were employed to estimate the proportion of the
outcome according to the desired cut-off. Normality was assumed ifRecords idenfied through 
database searching
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pregnancy outcomes, EClinicalMedicine (2020), https://doi.org/10.1016/jthe data were reported as mean and standard deviation. Normality
was assumed for data reported as median and interquartile range
only when the distribution was symmetrical. Meta-regression analy-
ses were conducted for a few key clinical outcomes (maternal inten-
sive care unit admission, maternal death, perinatal death, neonatal
PCR positivity), if meta-analytical summaries indicated significant
heterogeneity. All potential confounders were tested and those that
explain the heterogeneity (p value for beta <0.05 and p value for
residual heterogeneity >0.05) were reported. Potential publication
bias was assessed using Egger’s test and the creation of funnel plots
for visual inspection when and if enough studies (N>10) were avail-
able.[11] Analyses were conducted using R for statistical computing
software and meta package.
3. Results
3.1. General characteristics
Of 283 articles identified, 114 full manuscripts were assessed fur-
ther for eligibility and 86 studies were included (Figure 1, Supple-
mentary Table 2) [12-93]. Of those, 17 studies (2567 pregnancies)
that report on all available cases over a definite time period and suffi-
ciently large sample size (N>15) were included in the quantitativeAddional records idenfied 
through other sources
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Table 1
Summary and quality assessment of studies included in the quantitative synthesis.
Author, year Region/Country Women with
COVID-19
Included outcomes Severe COVID-19* Proportion receiving antiviral
treatment and used regimen
(combinations of listed drugs)
Maternal mortality Newcastle-Ottawa
Scale score and/or
overall judgement
Pereira A, 2020 Madrid, Spain 60 Symptoms, maternal characteristics, lab-
oratory parameters, pregnancy and
neonatal outcomes
2/60 Hydroxychloroquine, lopinavir,
ritonavir, darunavir, tocilizu-
mab, cobicistat 35%, (21/60)
0/60 $ $ $ $ /$ $ /$$ $
High
Duffy C, 2020 Boston, USA 15 Laboratory parameters Not extractable Not reported Not reported Moderate
Lokken E, 2020 Washington, USA 46 Symptoms, maternal characteristics, lab-
oratory parameters, pregnancy
outcomes
6/46 Remdesivir, hydroxychloro-
quine, 6.5% (3/46)
0/46 High
Qadri F, 2020 Michigan, USA 16 Maternal characteristics, laboratory
parameters, pregnancy and neonatal
outcomes
0/16 Remdesivir, hydroxychloro-
quine, 12.5% (2/16)
0/16 High
Yan J, 2020 Within and outside of
Hubei Province, China
65 Pregnancy and neonatal outcomes 6/65 Oseltamivir, ganciclovir, arbidol,
peramivir, interferon, aciclo-
vir, ribavirin, 9.2% (6/65)
0/65 High
Chen L, 2020 Hubei Province, Wuhan, China 84 Symptoms, maternal characteristics Not extractable Not reported 0/84 High
Andrikopoulou M, 2020 New York, USA 158 Maternal characteristics, laboratory
parameters, maternal outcomes
Not extractable Not reported 0/158 High
Knight M, 2020 National, UK 427 Symptoms, maternal characteristics,
pregnancy and neonatal outcomes
Not reported Oseltamivir, lopinavir, ritonavir
2.1% (9/427)
5/427 $ $ $ /$$ /$ $$
High
Williams R, 2020 New York, Philadelphia,
New Jersey, Ohio, USA
64 Maternal characteristics, pregnancy and
neonatal outcomes
64/64 Remdesivir, hydroxychloro-
quine, ~81% (52/64)
0/64 $ $ $ /$$ /$ $$
High
Savasi M, 2020 Lombardi, Italy 77 Symptoms, maternal characteristics, lab-
oratory parameters, pregnancy and
neonatal outcomes
14/77 Lopinavir, ritonavir, remdesivir,
darunavir, 32.5% (25/77)
0/77 $ $ $ /$$ /$ $
High
London V, 2020 New York, USA 68 Symptoms, maternal characteristics, lab-
oratory parameters, pregnancy and
neonatal outcomes
Not extractable Hydroxychloroquine, 20.6% (16/
68)
0/68 $ $ $ /$$ /$ $
High
Goldfarb I, 2020 Massachusetts, USA 61 Maternal characteristics, pregnancy and
neonatal outcomes
Not reported Not reported 0/61 $ $ $ /$$ /$ $
High
Kayer G, 2020 National, France 617 Symptoms, maternal characteristics,
pregnancy and neonatal outcomes
128/617 Not reported 1/617 $ $ $ $ /$ $ /$$ $
High
Romagano M,2020 New Jersey, USA 73 Maternal outcomes Not extractable Not extractable 0/73 Moderate
Mendoza M, 2020 Barcelona, Spain 42 Maternal characteristics, maternal
outcomes
8/42 Not reported 0/42 $ $ $ /$$ /$ $
High
NethOSS registry, 2020 National,Netherlands 210 Symptoms, pregnancy and neonatal
outcomes
Not reported Remdesivir, Oseltamivir, 1.4% (3/
210)
1/210 High
Brazilian registry, 2020 National, Brazil 484 Symptoms, maternal characteristics,
maternal outcomes
Not reported Not specified, 42% (121/288) 36/484 High
PCR: polymerase chain reaction, COVID-19: coronavirus disease 2019.
*As defined by individual studies.
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A. Khalil et al. / EClinicalMedicine 00 (2020) 100446 5synthesis [12-28]. Other small case series and case reports were used
to extract rarely reported events and outcome such as maternal or
neonatal mortality, evidence for vertical transmission or placental
pathologies [29-97]. Quality was moderate to high for the included
studies (Table 1). The main weaknesses were retrospective design
and inconsistent definition and reporting of outcomes. There were
five reports from national registries (UK, Netherlands, China, France
and Brazil), while the rest were regional reports from other countries
(Italy, USA, Spain) (Table 1). One study strictly included only women
with severe and critical COVID-19 [20]. Uptake of antiviral treatments
and the drug regimens used varied significantly among the countries
(Table 1). The included outcomes from individual studies can beTable 2
Pooled proportions of presenting symptoms, maternal charact
comes in pregnant women with reverse transcription polym
infection.
Studi
Symptoms at presentation
Asymptomatic 10
Fever 10
Cough 10
Loss of taste or smell 3
Myalgia, limb or joint pain 4
Fatigue, tiredness 3
Headache 4
Shortness of breath 9
Chest pain, tightness 2
Diarrhoea 6
Maternal and pregnancy characteristics
Maternal age >35 years 8
Black, Asian or minority ethnic 9
Obesity (BMI >30 kg/m2) 9
Smoker 4
Asthma 7
Chronic hypertension 8
Cardiac disease 2
Any comorbidity 5
Third trimester 8
Laboratory findingsy
Raised D-dimer 2
Raised C-reactive protein or procalcitonin 6
Lymphopenia 7
Thrombocytopenia 3
Elevated AST levels 4
Treatments received
Antiviral treatment 10
Anticoagulation 2
Maternal complications
Bacteria or viral co-infection{ 1
Maternal intensive care unit admission 13
Oxygen support (nasal or non-invasive ventilation) 10
Intubation and mechanical ventilation 11
Maternal ECMO 12
Maternal death 15
Obstetric outcomes
Delivered cases 10
Delivery due to COVID-19 related reasons 8
Delivery due to fetal distress 6
Preterm birth (any) 10
Spontaneous preterm birth 7
Medically indicated preterm birth 6
Preterm birth < 34+0 weeks 4
Caesarean delivery 10
Perinatal outcomes
Perinatal death
Stillbirthyy 8
Neonatal death 8
SARS-CoV-2 PCR positivity after delivery 9
AST: Aspartate Transaminase, ECMO: Extra-Corporeal Membra
ase chain reaction, CI: confidence interval, n: numerator, N: de
*Random-intercept logistic regression meta-analysis with cont
y Abnormal according to local reference range.
{Any bacterial or viral respiratory pathogen (mycoplasma, influ
yyWhen total births were used as the denominator, the rate of
Please cite this article as: A. Khalil et al., SARS-CoV-2 infection in pregna
pregnancy outcomes, EClinicalMedicine (2020), https://doi.org/10.1016/jfound in Table 1. Publication bias was assessed for outcome with
more than 10 included studies (Supplementary Table 3). The funnel
plot asymmetry tests suggested possible publication bias in maternal
intensive care unit admission (bias -2.61, p=0.013) and maternal
death (bias -2.85, p=0.001). Two reports from China had risk of over-
lap and the study with more comprehensive reporting or larger num-
bers was used for each outcome [16,17].
3.2. Clinical symptoms, laboratory and imaging findings
Table 2 presents pooled proportions for our primary analysis of 17
reports. Most women presented with fever and cough, althougheristics, laboratory findings, treatments and clinical out-
erase chain reaction (RT-PCR) confirmed SARS-CoV-2
es (N) Cases (n/N) Proportion (95% CI)* I[2]
253/1205 14.5% (5.632.5%) 97.0%
1292/1987 63.3% (54.771.2%) 91.7%
1391/1987 71.4% (66.276.2%) 79.4%
194/635 22.9% (11.640.1%) 87.2%
104/640 18.9% (9.733.5%) 89.9%
101/545 18.5% (15.522.0%) 0.0%
92/640 15.0% (8.924.1%) 78.4%
789/1941 34.4% (25.744.4%) 93.9%
30/170 17.5% (9.829.2%) 62.5%
126/1621 7.4% (5.410.0%) 58.8%
504/1524 30.6% (25.136.6%) 77.5%
621/1104 50.8% (38.363.2%) 92.3%
509/1725 38.2% (23.655.4%) 97.0%
39/1155 3.3% (2.24.9%) 21.9%
126/1661 8.8% (5.913.1%) 79.4%
68/1710 4.2% (2.56.9%) 72.3%
26/715 3.2% (1.09.7%) 84.4%
252/776 32.5% (29.335.8%) 0.0%
900/1223 73.9% (63.782.1%) 91.4%
77/91 84.6% (75.790.7%) 0.0%
144/351 54.0% (16.587.5%) 97.5%
143/444 34.2% (24.944.8%) 75.1%
7/259 3.2% (0.910.7%) 62.9%
48/318 16.0% (10.723.2%) 48.8%
291/1321 21.1% (7.945.5%) 97.6%
69/141 51.1% (21.280.3%) 92.5%
5/60 8.3% (3.518.5%) 
159/1591 7.0% (4.410.9%) 81.7%
295/1623 18.2% (9.831.1%) 95.5%
92/1680 3.4% (1.57.7%) 90.2%
13/1896 0.7% (0.41.2%) 0.0%
43/2468 0.9% (0.42.3%) 73.4%
746/1650 52.4% (37.966.5%) 96.1%
95/497 19.0% (8.936.0%) 89.4%
15/238 5.3% (2.311.8%) 40.2%
183/746 21.8% (14.631.3%) 82.3%
22/440 5.0% (3.37.5%) 0.0%
92/430 18.4% (8.335.8%) 87.4%
13/147 3.3% (0.231.9%) 87.0%
390/746 48.3 (34.162.7%) 91.5%
12/1362 0.9% (0.51.5%) 0.0%
4/688 0.6% (0.21.5%) 0.0%
19/751 1.4% (0.44.7%) 59.8%
ne Oxygenation, RT-PCR: reverse-transcription polymer-
nominator.
inuity correction.
enza, respiratory syncytial virus, etc.).
stillbirth was 16.1 per 1000 births.
ncy: A systematic review and meta-analysis of clinical features and
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dyspnoea (35%), had the characteristic anosmia, or non-specific
complaints of myalgia, fatigue, or headache (~15-20%). Less than
one fifth were asymptomatic, although this too varied substan-
tially between reports. Black, Asian or ethnic minorities (BAME)
were common in the included reports (~50%). The rates of obesity
(38.2%) and comorbidities were also high (32.5%) (Figure 2). Most
women (~75%) were in the third trimester or postpartum at the
time of reporting. Investigations revealed that most had raised
inflammatory markers of C-reactive protein or procalcitonin, and
around one third had lymphopenia; raised liver enzymes compli-
cated 16.0%. Thrombocytopenia was rare. Raised D-Dimer levels
were very common (~85%) but reports did not include preg-
nancy-specific normal ranges.
3.3. Maternal complications
Few women had evidence of co-infection, bacterial or viral.
Admission to intensive care unit occurred in ~7% of women, withFig. 2. Forest plot of pooled proportion of (a) black, Asian or minority ethnic, (b) obesi
Please cite this article as: A. Khalil et al., SARS-CoV-2 infection in pregna
pregnancy outcomes, EClinicalMedicine (2020), https://doi.org/10.1016/jor without respiratory support, with the upper 95% CI 11%
(Figure 3). 43 of 2468 women died with a pooled proportion of
0.9% according to inverse variance proportion regression meta-
analysis. Invasive mechanical ventilation support and extracorpo-
real membrane oxygenation were uncommon (3.4% and 0.7%,
respectively).
3.4. Obstetric and perinatal outcomes
Preterm birth, primarily iatrogenic, was common, in around
one fifth of cases, with variability between studies (Figure 4). Half
of births were by caesarean section (Figure 4). While few studies
reported indications, the most common indication was not fetal
distress, but related to COVID-19, severe maternal pneumonia, or
fear of sudden maternal decompensation. The spontaneous pre-
term delivery rate was within expected ranges. Perinatal deaths
occurred in less than 1%; there were twelve stillbirths and four
neonatal deaths. The rate of neonatal SARS-CoV-2 positivity was
~1-2% (Figure 5).ty and (c) chronic co-morbidities in pregnant women with confirmed COVID-19.
ncy: A systematic review and meta-analysis of clinical features and
.eclinm.2020.100446
Fig. 3. Forest plot of pooled proportion of maternal intensive care unit admission in pregnant women with confirmed COVID-19.
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Significant heterogeneity was observed in three of the four critical
outcomes (maternal intensive care unit admission, maternal death,
neonatal PCR positivity). Meta-regression analysis showed that the
statistical heterogeneity in maternal intensive care unit admission
was explained by the presence of maternal co-morbidities
(beta=0.007, p<0.05) and maternal age over 35 years (beta=0.007,
p<0.01). Heterogeneity in maternal death was explained by the use
of antiviral treatment (beta=0.026, p<0.001). Neonatal SARS-CoV-2
PCR positivity was explained by spontaneous preterm delivery
(beta=0.19, p<0.05) (Supplementary Table 4). Maternal admission to
intensive care unit was more common in cohorts with a higher rate
of maternal co-morbidities and older maternal age. Neonatal SARS-
CoV-2 positivity was higher in cohorts with higher spontaneous pre-
term birth rate. Maternal mortality appeared to be higher in
cohorts with more reported use of antiviral treatment. However,
this is likely to be explained by a residual confounder not
accounted for in this analysis. Third trimester pregnancy, BAME
background and obesity did not adequately explain the heteroge-
neity in maternal intensive care unit admission, maternal death
or neonatal SARS-CoV-2 positivity.
4. Rare outcome events reported in small case series and case
reports
Analysis of conception products that may be associated with verti-
cal transmission were reported in a minority of cases (placenta:
10.7%, amniotic fluid: 5.5%, cord blood: 6.2%; Supplementary Table
5). Maternal bodily fluid PCR positivity was rare (vaginal swab: 0%,
stool: 12.5%, breast milk: 6.7%). Neonatal and maternal mortality fig-
ures were higher (2-3%) in case reports owing to reporting bias. There
were 65 placental pathology reports available, with inflammatory
changes documented in one fifth (Supplementary Table 6). 42 placen-
tal pathology reports were available for maternal or fetal malperfu-
sion findings, which were very common (78.6%).
5. Discussion
In this systematic review, we summarise the published, peer-
reviewed information about women with confirmed COVID-19 in
pregnancy. Women usually presented with fever and cough. The
prevalence of BAME background and maternal comorbidities was
high. Most show biochemical evidence of inflammation, mainly lym-
phopenia. Many received antiviral therapy and few have beenPlease cite this article as: A. Khalil et al., SARS-CoV-2 infection in pregna
pregnancy outcomes, EClinicalMedicine (2020), https://doi.org/10.1016/jadmitted to intensive care. Pregnancy outcomes were generally
good, although there is little information about early pregnancy
exposure, but iatrogenic preterm birth was common. Perinatal and
maternal mortality were rare (<1%). Neonatal SARS-CoV-2 PCR posi-
tivity was rare but vertical transmission seems probable as the infor-
mation on the SARS-CoV-2 positivity of other biological samples
(maternal, conception products, fetal or neonatal) accrues.
This comprehensive search was without language restriction,
yielding a large number of included studies with 2567 pregnan-
cies in the quantitative synthesis. We strove to identify potential
duplicate reports by cross-checking cases reported from the same
centres and, when there was doubt, excluded those studies. We
performed proportion meta-analysis for outcomes with suffi-
ciently large cohorts, while we provided narrative summaries for
rare outcomes from small case series and reports. Finally, we per-
formed meta-regression analyses to explore the heterogeneity in
critical clinical outcomes
The major limitations of this review are the retrospective
design (especially case series and reports), the lack of universal
testing for SARS-CoV-2 (given that up to 90% of pregnant women
who are infected with SARS-CoV-2 are asymptomatic [98]), and
the lack of standardised antenatal surveillance, management, tim-
ing and mode of delivery of women with COVID-19. The lack of
standardised symptom and outcome queries and reporting did
not allow for reporting mutually exclusive categories. The trans-
formation of maternity care services worldwide may result in
indirect effects of COVID-19 on maternal and perinatal outcomes,
and these are currently unmeasured. A significant proportion of
pregnancies were affected by COVID-19 in the third trimester and
then delivered, so we were unable to comment meaningfully on
outcomes related to early pregnancy exposure or those that take
time to develop, such as fetal growth restriction. Despite detect-
ing significant publication bias for only two investigated out-
comes, it is likely that publication bias is a problem for all
reported outcomes. However, there is no methodological or sta-
tistical way of preventing such bias at this time, and this must be
acknowledged as a limitation. Finally, there are press reports of
adverse outcomes that have not yet appeared in the peer
reviewed literature, so serious complications such as maternal
death or stillbirth are likely currently under-reported; however,
we excluded press reports because we would be unable to ascer-
tain duplicate cases.
Data from non-pregnant adults in China have described the most
common presenting symptoms of COVID-19 as fever and cough, [99]
as in our review. However, in the UK, patient-reported outcomesncy: A systematic review and meta-analysis of clinical features and
.eclinm.2020.100446
Fig. 4. Forest plots of pooled proportion of (a) preterm birth, (b) spontaneous and (c) medically indicated preterm birth, and (d) caesarean section in pregnant women with con-
firmed SARS-CoV-2 infection.
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Fig. 5. Forest plot of pooled proportion of neonatal SARS-CoV-2 positivity in babies born to women with confirmed COVID-19.
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(80%) and loss of taste and smell (59%), along with persistent cough
(58%) and dyspnoea (49%); fever was less prominent (32%) [100].
These differences could relate to unstructured assessment of symp-
toms, varying criteria for formal SARS-CoV-2 testing, or pregnancy-
induced changes in the immune system.
The need for intensive care in pregnant women with COVID-
19 in our review is slightly higher than that for infected non-
pregnant women of reproductive age, thought to be no higher
than 4.2% [101]. While reassuring, the proportion of women
admitted to an intensive care unit was affected by the presence
of maternal comorbidities and possibly by additional confounders
not accounted for in this review. Furthermore, there was signifi-
cant publication bias in the analysis, intensive care unit admission
criteria was not defined and may vary between studies. Therefore,
it is not possible to verify or refute an increased risk of intensive
care unit admission for pregnant women. While national pro-
grams investigating maternal deaths will report the relevant data,
this will take time and will not inform care during the current
pandemic.
This review provides information required to guide current care
during the SARS-CoV-2 pandemic. Key knowledge gaps include the
relationship between infection and outcomes for all pregnant
women, based on universal (not symptoms-based) testing and struc-
tured enquiry about symptoms. We lack information about meaning-
ful numbers of women infected in early pregnancy and about the
indications for iatrogenic preterm delivery and caesarean section,
particularly in relation to local practice. We lack information on the
indirect effects of COVID-19 on pregnancy outcomes; given the dra-
matic changes seen in maternity care services in order to deliver gov-
ernment-mandated social distancing and lockdown for non-essential
services, these effects on pregnancy outcomes may be as great, if not
greater, than the direct effects of the virus. The relative increase in
stillbirth could be related to direct effects of SARS-CoV-2 and/or indi-
rect effects of COVID-19 (i.e., maternal care-seeking and/or changes
in maternity care service delivery). Finally, we need to support com-
prehensive assessment of potential vertical transmission to under-
stand whether it occurs and, if so, how and with what frequency. A
new study sponsored by Public Health England to address these
questions is ongoing (www.pericovid.com); whenever possible,
serum samples from neonates born to SARS-CoV-2 positive mothers
should be stored until robust immunological testing is available, as
advised by the Royal College of Paediatrics and Child Health, UK.
Knowledge of safety and protective immunity will inform the role for
COVID-19 vaccines in pregnant women. It is also necessary to put in
place mechanisms for long-term follow-up of babies of infected
mothers.
The evidence to date is reassuring with regards to the risks of
COVID-19 in pregnancy. The risk of maternal intensive care unitPlease cite this article as: A. Khalil et al., SARS-CoV-2 infection in pregna
pregnancy outcomes, EClinicalMedicine (2020), https://doi.org/10.1016/jadmission is likely to be similar to that in other women of repro-
ductive age when summary aggregates are compared to available
data from Centers for Disease Control and Prevention from the
United States [101]. While pregnancy outcomes are generally
good, iatrogenic preterm birth appears to be increased, and verti-
cal transmission is a possibility for which we need more evi-
dence. Importantly, a critical gap in our knowledge is the impact
on pregnancy outcomes of the COVID-19-related transformation
of maternity care services.
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